<DOC>
	<DOC>NCT00570986</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of 2 doses of ABT-874 versus placebo in the treatment of subjects with moderate to severe plaque psoriasis.</brief_summary>
	<brief_title>A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject is &gt;= 18 years of age Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis Subject is judged to be in generally good health as determined by the principal investigator Subject has previous exposure to systemic antiIL 12 therapy Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy Subject is taking or requires oral or injectible corticosteroids Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medicationinduced or medicationexacerbated psoriasis or new onset guttate psoriasis Subject considered by the investigator, for any reason, to be an unsuitable candidate Female subject who is pregnant or breastfeeding or considering becoming pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Plaque Psoriasis</keyword>
</DOC>